CN110759941B - Preparation method of D-gluconic acid-gamma-lactone and intermediate thereof - Google Patents
Preparation method of D-gluconic acid-gamma-lactone and intermediate thereof Download PDFInfo
- Publication number
- CN110759941B CN110759941B CN201911205131.2A CN201911205131A CN110759941B CN 110759941 B CN110759941 B CN 110759941B CN 201911205131 A CN201911205131 A CN 201911205131A CN 110759941 B CN110759941 B CN 110759941B
- Authority
- CN
- China
- Prior art keywords
- lactone
- glucono
- gluconic acid
- replace
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- SXZYCXMUPBBULW-TXICZTDVSA-N D-glucono-1,4-lactone Chemical compound OC[C@@H](O)[C@H]1OC(=O)[C@H](O)[C@H]1O SXZYCXMUPBBULW-TXICZTDVSA-N 0.000 title claims abstract description 103
- 238000002360 preparation method Methods 0.000 title claims abstract description 51
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 claims abstract description 15
- 239000007787 solid Substances 0.000 claims abstract description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 45
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 42
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 35
- 238000006243 chemical reaction Methods 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 claims description 16
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 15
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 claims description 15
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 10
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 10
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- -1 dicarbonyl imidazole Chemical compound 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 7
- 238000002425 crystallisation Methods 0.000 claims description 7
- 230000008025 crystallization Effects 0.000 claims description 7
- 239000011698 potassium fluoride Substances 0.000 claims description 7
- 235000003270 potassium fluoride Nutrition 0.000 claims description 7
- QSUJAUYJBJRLKV-UHFFFAOYSA-M tetraethylazanium;fluoride Chemical compound [F-].CC[N+](CC)(CC)CC QSUJAUYJBJRLKV-UHFFFAOYSA-M 0.000 claims description 7
- 239000005051 trimethylchlorosilane Substances 0.000 claims description 7
- XTUVJUMINZSXGF-UHFFFAOYSA-N N-methylcyclohexylamine Chemical compound CNC1CCCCC1 XTUVJUMINZSXGF-UHFFFAOYSA-N 0.000 claims description 6
- PAMIQIKDUOTOBW-UHFFFAOYSA-N N-methylcyclohexylamine Natural products CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 229940043279 diisopropylamine Drugs 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- MOVBJUGHBJJKOW-UHFFFAOYSA-N methyl 2-amino-5-methoxybenzoate Chemical compound COC(=O)C1=CC(OC)=CC=C1N MOVBJUGHBJJKOW-UHFFFAOYSA-N 0.000 claims description 5
- 239000011775 sodium fluoride Substances 0.000 claims description 5
- 235000013024 sodium fluoride Nutrition 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 238000003828 vacuum filtration Methods 0.000 claims description 4
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 claims 2
- OATWCNSODQAOQC-UHFFFAOYSA-N [SiH4].Br Chemical compound [SiH4].Br OATWCNSODQAOQC-UHFFFAOYSA-N 0.000 claims 1
- XJINZNWPEQMMBV-UHFFFAOYSA-N n-methylhexan-1-amine Chemical compound CCCCCCNC XJINZNWPEQMMBV-UHFFFAOYSA-N 0.000 claims 1
- 238000000967 suction filtration Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 45
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 abstract description 9
- 235000012209 glucono delta-lactone Nutrition 0.000 abstract description 9
- 229910000077 silane Inorganic materials 0.000 abstract description 8
- 238000009776 industrial production Methods 0.000 abstract description 6
- 239000007858 starting material Substances 0.000 abstract description 6
- 238000003912 environmental pollution Methods 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 229960003681 gluconolactone Drugs 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 239000000543 intermediate Substances 0.000 description 49
- 238000012360 testing method Methods 0.000 description 43
- 239000000523 sample Substances 0.000 description 33
- 239000013068 control sample Substances 0.000 description 11
- 238000005906 dihydroxylation reaction Methods 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 8
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 4
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 4
- 229950006191 gluconic acid Drugs 0.000 description 4
- 235000012208 gluconic acid Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000005046 Chlorosilane Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- VQPFDLRNOCQMSN-UHFFFAOYSA-N bromosilane Chemical compound Br[SiH3] VQPFDLRNOCQMSN-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 150000002222 fluorine compounds Chemical group 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- AGVKXDPPPSLISR-UHFFFAOYSA-N n-ethylcyclohexanamine Chemical compound CCNC1CCCCC1 AGVKXDPPPSLISR-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000013094 purity test Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
- C07F7/1872—Preparation; Treatments not provided for in C07F7/20
- C07F7/188—Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of Si-O linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
技术领域technical field
本发明属于医药化工技术领域,更具体地说,它涉及一种D-葡萄糖酸-γ-内酯及其中间体的制备方法。The invention belongs to the technical field of medicine and chemical industry, and more particularly relates to a preparation method of D-glucono-γ-lactone and an intermediate thereof.
背景技术Background technique
D-葡萄糖酸-γ-内酯[CAS:1198-69-2]是葡萄酸内酯类化合物,作为蛋内酯蛋白凝固剂、保鲜剂、色调保鲜剂、酸味剂已广泛地应用到食品添加剂领域。近几年随着抗糖尿病药物研究领域的发展,作为糖尿病药物得主要组成部分,其应用价值逐步提高。因此,开发D-葡萄糖酸-γ-内酯的新的工艺路线十分必要。D-glucono-γ-lactone [CAS: 1198-69-2] is a gluconolactone compound, which has been widely used in food additives as egg lactone protein coagulant, preservative, color preservative and sour agent field. In recent years, with the development of the research field of anti-diabetic drugs, as the main component of diabetes drugs, its application value has gradually increased. Therefore, it is necessary to develop a new process route of D-glucono-γ-lactone.
D-葡萄糖酸-γ-内酯传统的合成方法以文献Journal of CarbohydrateChemistry,26(5&6),329-338;2007是以D-(+)-葡萄糖,为起始物料,在氯化钙和碳酸钙和水条件下制备D-葡萄糖酸,然后溶解在二氧六环和水溶剂中制备D-葡萄糖酸-1,5-内酯,D-葡萄糖酸-1,5-内酯在乙酸和盐酸条件下转化为D-葡萄糖酸-γ-内酯。上述操作的总收率仅为48.8%,反应操作步骤多,且产率较低,不利于大规模的生产。The traditional synthesis method of D-glucono-γ-lactone is based on the literature Journal of Carbohydrate Chemistry, 26(5&6), 329-338; 2007, with D-(+)-glucose as the starting material, in calcium chloride and carbonic acid D-gluconic acid was prepared under calcium and water conditions, then dissolved in dioxane and water solvent to prepare D-glucono-1,5-lactone, D-glucono-1,5-lactone in acetic acid and hydrochloric acid Converted to D-glucono-γ-lactone under conditions. The total yield of the above operation is only 48.8%, the reaction operation steps are many, and the yield is low, which is unfavorable for large-scale production.
另外,在专利WO2006005070文献报道,以D-葡萄糖酸为起始物料,在水溶剂中通过高温转化为D-葡萄糖酸-γ-内酯和D-葡萄糖酸-1,5-内酯混合物。但是上述操作不利于产物的纯化和分离,因此采用上述方式得到的D-葡萄糖酸-γ-内酯的纯度较低。In addition, it is reported in the patent WO2006005070 that D-gluconic acid is used as a starting material, and is converted into a mixture of D-glucono-γ-lactone and D-glucono-1,5-lactone by high temperature in an aqueous solvent. However, the above operation is not conducive to the purification and separation of the product, so the purity of the D-glucono-γ-lactone obtained by the above method is relatively low.
发明内容SUMMARY OF THE INVENTION
针对现有技术存在的不足,本发明的目的在于提供一种D-葡萄糖酸-γ-内酯中间体的制备方法,所需原料及试剂便宜,成本低廉,操作简捷安全,收率高,产率稳定,同时环境污染小,有很好的经济效应,适宜工业生产。In view of the deficiencies in the prior art, the object of the present invention is to provide a preparation method of a D-glucono-γ-lactone intermediate, the required raw materials and reagents are cheap, the cost is low, the operation is simple and safe, the yield is high, and the yield is high. The rate is stable, the environmental pollution is small, and the economic effect is very good, which is suitable for industrial production.
为实现上述目的,本发明提供了如下技术方案:一种D-葡萄糖酸-γ-内酯中间体的制备方法,包括以D-葡萄糖内酯为起始物料,在碱性试剂、DMAP的条件下与硅烷基试剂RX反应,结晶纯化后得到高纯度的固体D-葡萄糖酸-γ-内酯中间体。In order to achieve the above purpose, the present invention provides the following technical scheme: a preparation method of a D-glucono-γ-lactone intermediate, comprising using D-glucolactone as a starting material, under the conditions of an alkaline reagent and DMAP It reacts with silane-based reagent RX, and obtains high-purity solid D-gluconic acid-γ-lactone intermediate after crystallization and purification.
通过采用上述技术方案,在碱性试剂、DMAP的条件下,此时D-葡萄糖内酯可以硅烷基试剂RX反应得到D-葡萄糖酸-γ-内酯中间体,上述操作不仅所需原料及试剂便宜,成本低廉,操作简捷安全,收率高,产率稳定;同时环境污染小,有很好的经济效应,适宜工业生产。By adopting the above technical scheme, under the condition of alkaline reagent and DMAP, D-glucolactone can be reacted with silyl reagent RX to obtain D-glucono-γ-lactone intermediate. The above operation not only requires raw materials and reagents Inexpensive, low cost, simple and safe operation, high yield, stable yield; at the same time, the environmental pollution is small, has good economic effect, and is suitable for industrial production.
进一步的,所述硅烷基试剂RX选自C1-C12硅烷试剂,所述C1-C12硅烷试剂为三甲基氯硅烷、三乙基氯硅烷、三甲基溴硅烷、三乙基溴硅烷、叔丁基二甲硅基三氟甲磺酸酯中的一种或多种。Further, the silane-based reagent RX is selected from C 1 -C 12 silane reagents, and the C 1 -C 12 silane reagent is trimethylchlorosilane, triethylchlorosilane, trimethylbromosilane, triethylsilane One or more of bromosilane and tert-butyldimethylsilyl trifluoromethanesulfonate.
进一步的,所述碱性试剂为二甲胺,二异丙基胺、咪唑、二羰基咪唑、吗啉、N-甲基吗啉、N-甲基环己胺、N-乙基环基胺、三乙胺、N,N'-二异丙基乙胺、二环己胺的一种或多种。Further, the basic reagent is dimethylamine, diisopropylamine, imidazole, dicarbonyl imidazole, morpholine, N-methylmorpholine, N-methylcyclohexylamine, N-ethylcyclylamine , one or more of triethylamine, N,N'-diisopropylethylamine and dicyclohexylamine.
通过采用上述技术方案,二甲胺,二异丙基胺、咪唑、二羰基咪唑、吗啉、N-甲基吗啉、N-甲基环己胺、N-乙基环基胺、三乙胺、N,N'-二异丙基乙胺、二环己胺均是常见的C1-C12硅烷试剂,而二甲胺,二异丙基胺、咪唑、二羰基咪唑、吗啉、N-甲基环己胺、N-乙基环基胺、二环己胺均是常见的碱性试剂,通过加入上述C1-C12硅烷试剂和碱性试剂中的任意一项均可使得D-葡萄糖内酯与相对应的硅烷基试剂RX反应,从而得到D-葡萄糖酸-γ-内酯中间体。By adopting the above technical solutions, dimethylamine, diisopropylamine, imidazole, dicarbonyl imidazole, morpholine, N-methylmorpholine, N-methylcyclohexylamine, N-ethylcyclylamine, triethylamine Amine, N,N'-diisopropylethylamine, dicyclohexylamine are all common C 1 -C 12 silane reagents, while dimethylamine, diisopropylamine, imidazole, dicarbonyl imidazole, morpholine, N-methylcyclohexylamine, N-ethylcyclohexylamine, and dicyclohexylamine are all common alkaline reagents. By adding any one of the above C 1 -C 12 silane reagents and alkaline reagents, the D-gluconolactone reacts with the corresponding silane-based reagent RX to give D-glucono-γ-lactone intermediate.
进一步的,所述碱性试剂的投料量与葡萄糖内酯的比例为4.0倍当量以上。Further, the ratio of the feeding amount of the alkaline reagent to the glucolactone is more than 4.0 times the equivalent.
进一步的,上述碱性试剂的投料量与葡萄糖内酯的比例优选为4.5倍。Further, the ratio of the feeding amount of the above-mentioned alkaline reagent to the glucolactone is preferably 4.5 times.
通过采用上述技术方案,通过控制加入的碱性试剂的用量,可以有效控制得到的D-葡萄糖酸-γ-内酯中间体的纯度。By adopting the above technical scheme, by controlling the amount of the added alkaline reagent, the purity of the obtained D-glucono-γ-lactone intermediate can be effectively controlled.
进一步的,反应温度为-20~80℃。Further, the reaction temperature is -20 to 80°C.
进一步的,反应温度优选为-5~25℃。Further, the reaction temperature is preferably -5 to 25°C.
通过采用上述技术方案,通过控制具体反应温度,由此可以有效控制得到的D-葡萄糖酸-γ-内酯中间体的产率。By adopting the above technical scheme and controlling the specific reaction temperature, the yield of the obtained D-glucono-γ-lactone intermediate can be effectively controlled.
进一步的,结晶纯化的具体操作是:经由GC检测反应完全后,再由布氏漏斗过滤,滤液水洗1-3遍,正庚烷萃取后,减压浓缩,并加入10个当量的正庚烷在25~-40℃的温度下结晶,即可得到D-葡萄糖酸-γ-内酯中间体。Further, the specific operation of crystallization and purification is: after the reaction is detected by GC, it is filtered through a Buchner funnel, the filtrate is washed 1-3 times with water, extracted with n-heptane, concentrated under reduced pressure, and added with 10 equivalents of n-heptane. The D-glucono-γ-lactone intermediate can be obtained by crystallizing at a temperature of 25~-40°C.
通过采用上述技术方案,经由正庚烷进行结晶,可以有效的控制得到的D-葡萄糖酸-γ-内酯中间体的纯度。The purity of the obtained D-glucono-γ-lactone intermediate can be effectively controlled by adopting the above technical scheme and crystallizing through n-heptane.
针对现有技术存在的不足,本发明的另一目的在于提供一种D-葡萄糖酸-γ-内酯的制备方法,不仅操作方法简单,而且环境污染小,产率高,适合工业生产。In view of the deficiencies in the prior art, another object of the present invention is to provide a preparation method of D-glucono-γ-lactone, which is not only simple in operation, but also has little environmental pollution and high yield, and is suitable for industrial production.
为实现上述另一目的,本发明提供了如下技术方案:一种D-葡萄糖酸-γ-内酯的制备方法,利用所述的D-葡萄糖酸-γ-内酯中间体,在脱羟基保护试剂的作用下,得到D-葡萄糖酸-γ-内酯。In order to achieve the above-mentioned another purpose, the present invention provides the following technical scheme: a preparation method of D-gluconic acid-γ-lactone, using the D-gluconic acid-γ-lactone intermediate, in the protection of dehydroxylation Under the action of the reagent, D-glucono-γ-lactone is obtained.
通过采用上述技术方案,一步即可实现D-葡萄糖酸-γ-内酯的合成,且上述采用的试剂对于环境的污染小,其得到的产率较高,适合工业生产。By adopting the above technical scheme, the synthesis of D-glucono-γ-lactone can be realized in one step, and the above-mentioned reagent has little pollution to the environment, and the obtained yield is high, which is suitable for industrial production.
进一步的,所述脱羟基保护试剂为酸,所选酸为硫酸、盐酸、硝酸、磷酸、甲磺酸、三氟甲磺酸、对甲苯磺酸、甲酸、乙酸、三氟乙酸、丙酸、柠檬酸、酒石酸、马来酸、富马酸中的一种或多种。Further, the dehydroxylation protection reagent is an acid, and the selected acid is sulfuric acid, hydrochloric acid, nitric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, p-toluenesulfonic acid, formic acid, acetic acid, trifluoroacetic acid, propionic acid, One or more of citric acid, tartaric acid, maleic acid, and fumaric acid.
进一步的,所述脱羟基保护试剂为氟化物,所选氟化物为四甲基氟化铵、四乙基氟化铵、四丁基氟化铵、氟化铯、氟化钠或氟化钾中的一种。Further, the dehydroxylation protection reagent is fluoride, and the selected fluoride is tetramethylammonium fluoride, tetraethylammonium fluoride, tetrabutylammonium fluoride, cesium fluoride, sodium fluoride or potassium fluoride one of the.
进一步的,在脱羟基保护试剂的作用后还具有提纯结晶操作是:减压浓缩,加入150-300ml的乙醇加热溶解后,冷却至室温,加入少量晶种,析出固体,过滤后即可得到D-葡萄糖酸-γ-内酯。Further, after the action of the dehydroxylation protective reagent, there is also a purification and crystallization operation: concentration under reduced pressure, adding 150-300ml of ethanol for heating and dissolving, cooling to room temperature, adding a small amount of seed crystals, precipitating a solid, and filtering to obtain D. -Glucono-gamma-lactone.
通过采用上述技术方案,经由乙醇加热溶解,冷却后加入少量晶种进行结晶,可以有效提高得到的D-葡萄糖酸-γ-内酯的纯度。The purity of the obtained D-glucono-γ-lactone can be effectively improved by adopting the above technical scheme, dissolving by heating with ethanol, and adding a small amount of seed crystals after cooling for crystallization.
综上所述,本发明具有以下有益效果:本发明提供的制备方法所需原料及试剂便宜,成本低廉,操作简捷安全,收率高,产率稳定,同时环境污染小,有很好的经济效应,适宜工业生产。To sum up, the present invention has the following beneficial effects: the preparation method provided by the present invention requires cheap raw materials and reagents, low cost, simple and safe operation, high yield, stable yield, little environmental pollution, and good economy. effect, suitable for industrial production.
附图说明Description of drawings
图1为一种D-葡萄糖酸-γ-内酯中间体的制备方法实施例1中所得的D-葡萄糖酸-γ-内酯中间体的核磁共振氢谱图;Fig. 1 is a kind of D-gluconic acid-γ-lactone intermediate obtained in the preparation method Example 1 of a kind of D-gluconic acid-γ-lactone intermediate H NMR spectrogram;
图2为一种D-葡萄糖酸-γ-内酯中间体的制备方法实施例1中所得的D-葡萄糖酸-γ-内酯中间体的核磁共振碳谱图;Fig. 2 is the carbon nuclear magnetic resonance spectrogram of the D-gluconic acid-γ-lactone intermediate obtained in Example 1 of the preparation method of D-gluconic acid-γ-lactone intermediate;
图3为一种D-葡萄糖酸-γ-内酯的制备方法实施例1中所得的D-葡萄糖酸-γ-内酯的核磁共振氢谱图;Fig. 3 is a kind of D-gluconic acid-γ-lactone obtained in the preparation method Example 1 of D-gluconic acid-γ-lactone H NMR spectrogram;
图4为一种D-葡萄糖酸-γ-内酯的制备方法实施例1中所得的D-葡萄糖酸-γ-内酯的核磁共振碳谱图。4 is a carbon nuclear magnetic resonance spectrum of D-glucono-γ-lactone obtained in Example 1 of a preparation method of D-glucono-γ-lactone.
具体实施方式Detailed ways
以下结合附图对本发明作进一步详细说明。The present invention will be further described in detail below with reference to the accompanying drawings.
一、实施例1. Example
<1>、D-葡萄糖酸-γ-内酯中间体<1>, D-glucono-γ-lactone intermediate
实施例1:一种D-葡萄糖酸-γ-内酯中间体的制备方法,如图1所示,包括如下操作步骤:氮气保护下,将葡萄糖内酯(10.0g,56.2mmol)加入到100ml的四氢呋喃(THF),然后加入N-甲基环己胺(5.0eq)搅拌溶解后,加入0.5克的4-二甲氨基吡啶(DMAP),将反应体系冷却至-5℃,滴加三甲基氯硅烷(60ml,4.5当量),滴加完毕,室温搅拌30min,经GC检测反应完全,再由布氏漏斗进行减压抽滤,滤液水洗2次后,再采用100ml正庚烷萃取后,减压浓缩5分钟,然后加入10个当量的正庚烷在0℃结晶后得到白色固体。Embodiment 1: A preparation method of D-glucono-γ-lactone intermediate, as shown in Figure 1, includes the following operation steps: under nitrogen protection, adding glucolactone (10.0g, 56.2mmol) to 100ml of tetrahydrofuran (THF), then N-methylcyclohexylamine (5.0eq) was added and stirred to dissolve, 0.5 g of 4-dimethylaminopyridine (DMAP) was added, the reaction system was cooled to -5°C, and trimethylamine was added dropwise. Chlorosilane (60 ml, 4.5 equiv.) was added dropwise, stirred at room temperature for 30 min, and the reaction was complete as detected by GC, and then filtered through a Buchner funnel under reduced pressure. Concentrate under pressure for 5 minutes, then add 10 equivalents of n-heptane to give a white solid after crystallization at 0°C.
其中,上述合成D-葡萄糖酸-γ-内酯中间体的化学方程式为:Wherein, the chemical equation of above-mentioned synthetic D-gluconic acid-γ-lactone intermediate is:
葡萄糖内酯 D-葡萄糖酸-γ-内酯中间体Gluconolactone D-glucono-γ-lactone intermediate
如图1和图2所示,根据上述D-葡萄糖酸-γ-内酯中间体的核磁共振谱图,同时结合核磁共振氢谱的数据:As shown in Figure 1 and Figure 2, according to the nuclear magnetic resonance spectrum of the above-mentioned D-glucono-γ-lactone intermediate, combined with the data of the hydrogen nuclear magnetic resonance spectrum:
1H-NMR(CDCl3,400MHz)δ:0.05-0.18(m,36H),3.69-3.72(m,2H),4.03(d,1H),4.35-4.39(m,2H),4.54(d,1H)。 1 H-NMR (CDCl3, 400MHz)δ: 0.05-0.18(m, 36H), 3.69-3.72(m, 2H), 4.03(d, 1H), 4.35-4.39(m, 2H), 4.54(d, 1H) ).
由此可知,上述得到的白色固体就是D-葡萄糖酸-γ-内酯中间体。From this, it was found that the white solid obtained above was a D-glucono-γ-lactone intermediate.
实施例2:一种D-葡萄糖酸-γ-内酯中间体的制备方法,与实施例1的不同之处在于:反应体系冷却至0℃。Embodiment 2: a preparation method of a D-glucono-γ-lactone intermediate, which is different from Embodiment 1 in that the reaction system is cooled to 0°C.
实施例3:一种D-葡萄糖酸-γ-内酯中间体的制备方法,与实施例1的不同之处在于:反应体系冷却至25℃。Embodiment 3: a preparation method of a D-glucono-γ-lactone intermediate, the difference from Embodiment 1 is that the reaction system is cooled to 25°C.
实施例4:一种D-葡萄糖酸-γ-内酯中间体的制备方法,与实施例1的不同之处在于:反应体系冷却至-20℃。Embodiment 4: a preparation method of a D-glucono-γ-lactone intermediate, the difference from Embodiment 1 is that the reaction system is cooled to -20°C.
实施例5:一种D-葡萄糖酸-γ-内酯中间体的制备方法,与实施例1的不同之处在于:反应体系冷却至80℃。Embodiment 5: a preparation method of a D-glucono-γ-lactone intermediate, the difference from Embodiment 1 is that the reaction system is cooled to 80°C.
实施例6:一种D-葡萄糖酸-γ-内酯中间体的制备方法,与实施例1的不同之处在于:经GC检测反应完全,再由布氏漏斗进行减压抽滤,滤液水洗2次后,再采用150ml正庚烷萃取后,减压浓缩8分钟,然后加入10个当量的正庚烷在-40℃结晶。Embodiment 6: a kind of preparation method of D-gluconic acid-γ-lactone intermediate, the difference from Example 1 is: the reaction is complete through GC detection, then vacuum filtration is carried out by Buchner funnel, and the filtrate is washed with water for 2 After three times, extract with 150 ml of n-heptane, concentrate under reduced pressure for 8 minutes, and then add 10 equivalents of n-heptane to crystallize at -40°C.
实施例7:一种D-葡萄糖酸-γ-内酯中间体的制备方法,与实施例1的不同之处在于:经GC检测反应完全,再由布氏漏斗进行减压抽滤,滤液水洗2次后,再采用80ml正庚烷萃取后,减压浓缩3分钟,然后加入10个当量的正庚烷在25℃结晶。Embodiment 7: a kind of preparation method of D-gluconic acid-γ-lactone intermediate, the difference from Example 1 is: the reaction is completely detected by GC, then vacuum filtration is carried out by Buchner funnel, and the filtrate is washed with water for 2 After three times, extract with 80 ml of n-heptane, concentrate under reduced pressure for 3 minutes, then add 10 equivalents of n-heptane to crystallize at 25°C.
实施例8:一种D-葡萄糖酸-γ-内酯中间体的制备方法,与实施例1的不同之处在于:碱性试剂选用二甲胺。Embodiment 8: a preparation method of a D-gluconic acid-γ-lactone intermediate, which is different from Embodiment 1 in that dimethylamine is used as the alkaline reagent.
实施例9:一种D-葡萄糖酸-γ-内酯中间体的制备方法,与实施例1的不同之处在于:碱性试剂选用二异丙基胺。Embodiment 9: a preparation method of a D-gluconic acid-γ-lactone intermediate, which is different from Embodiment 1 in that the basic reagent is diisopropylamine.
实施例10:一种D-葡萄糖酸-γ-内酯中间体的制备方法,与实施例1的不同之处在于:碱性试剂选用二羰基咪唑和咪唑,二羰基咪唑和咪唑的重量百分比为1:1。Embodiment 10: a kind of preparation method of D-gluconic acid-γ-lactone intermediate, the difference with embodiment 1 is: basic reagent selects dicarbonyl imidazole and imidazole, and the weight percent of dicarbonyl imidazole and imidazole is 1:1.
实施例11:一种D-葡萄糖酸-γ-内酯中间体的制备方法,与实施例1的不同之处在于:硅烷基试剂RX为三乙基氯硅烷,用量为4.5当量。Embodiment 11: a preparation method of a D-gluconic acid-γ-lactone intermediate, the difference from Embodiment 1 is that the silyl reagent RX is triethylchlorosilane, and the amount is 4.5 equivalents.
实施例12:一种D-葡萄糖酸-γ-内酯中间体的制备方法,与实施例1的不同之处在于:硅烷基试剂RX为三甲基溴硅烷,用量为4.5当量。Embodiment 12: a preparation method of a D-gluconic acid-γ-lactone intermediate, which is different from Embodiment 1 in that the silyl reagent RX is trimethylbromosilane, and the amount is 4.5 equivalents.
实施例13:一种D-葡萄糖酸-γ-内酯中间体的制备方法,与实施例1的不同之处在于:硅烷基试剂RX为叔丁基二甲硅基三氟甲磺酸酯,用量为4.5当量。Embodiment 13: a preparation method of a D-gluconic acid-γ-lactone intermediate, the difference from Embodiment 1 is that the silyl reagent RX is tert-butyldimethylsilyl trifluoromethanesulfonate, The amount used was 4.5 equivalents.
实施例14:一种D-葡萄糖酸-γ-内酯中间体的制备方法,与实施例1的不同之处在于:硅烷基试剂RX为三乙基氯硅烷,用量为5当量。Embodiment 14: a preparation method of a D-gluconic acid-γ-lactone intermediate, which is different from Embodiment 1 in that the silyl reagent RX is triethylchlorosilane, and the amount is 5 equivalents.
实施例15:一种D-葡萄糖酸-γ-内酯中间体的制备方法,与实施例1的不同之处在于:硅烷基试剂RX为三乙基氯硅烷,用量为4.1当量。Embodiment 15: a preparation method of a D-gluconic acid-γ-lactone intermediate, the difference from Embodiment 1 is that the silyl reagent RX is triethylchlorosilane, and the amount is 4.1 equivalents.
<2>、D-葡萄糖酸-γ-内酯<2>, D-glucono-γ-lactone
实施例16:一种D-葡萄糖酸-γ-内酯的制备方法,包括如下操作步骤:在氮气保护下,将实施例1中制得的D-葡萄糖酸-γ-内酯中间体(50.0g,0.136mmol)加入到500ml的甲醇中,室温(20℃)按照100转/分钟搅拌溶解,15分钟后加入0.5克的氟化钾(KF),室温搅拌5小时,然后减压浓缩,加入200ml的乙醇加热溶解后,冷却至室温,加入少量晶种,析出固体。经布氏漏斗过滤后得到固体。Embodiment 16: a preparation method of D-gluconic acid-γ-lactone, comprising the following operation steps: under nitrogen protection, the D-gluconic acid-γ-lactone intermediate (50.0 g, 0.136 mmol) was added to 500 ml of methanol, stirred and dissolved at 100 rpm at room temperature (20°C), 0.5 g of potassium fluoride (KF) was added after 15 minutes, stirred at room temperature for 5 hours, then concentrated under reduced pressure, added After heating and dissolving 200 ml of ethanol, it was cooled to room temperature, a small amount of seed crystal was added, and a solid was precipitated. A solid was obtained after filtration through a Buchner funnel.
其中,上述合成D-葡萄糖酸-γ-内酯的化学方程式为:Wherein, the chemical equation of above-mentioned synthetic D-gluconic acid-γ-lactone is:
如图3和图4所示,根据上述D-葡萄糖酸-γ-内酯的核磁共振谱图,同时结合核磁共振氢谱的数据:As shown in Figure 3 and Figure 4, according to the above-mentioned NMR spectrum of D-glucono-γ-lactone, combined with the data of 1H NMR spectrum:
1H-NMR(d6-DMSO,400MHz)δ:3.4-3.5(m,1H),3.55-3.60(m,1H),3.75-3.79(m,1H),4.04-4.10(m,1H),4.13-4.16(m,1H),4.39-4.43(m,1H),4.65(t,J=5.5Hz,1H),4.95(d,J=6.0Hz,1H),5.59(d,J=4.5Hz,1H),6.22(m,d,J=5.5Hz,1H)。 1 H-NMR (d6-DMSO, 400MHz)δ: 3.4-3.5(m, 1H), 3.55-3.60(m, 1H), 3.75-3.79(m, 1H), 4.04-4.10(m, 1H), 4.13 -4.16(m,1H),4.39-4.43(m,1H),4.65(t,J=5.5Hz,1H),4.95(d,J=6.0Hz,1H),5.59(d,J=4.5Hz, 1H), 6.22 (m, d, J=5.5Hz, 1H).
由此可知,上述得到固体就是D-葡萄糖酸-γ-内酯。From this, it was found that the obtained solid was D-glucono-γ-lactone.
实施例17:一种D-葡萄糖酸-γ-内酯的制备方法,与实施例16的不同之处在于:所述脱羟基保护试剂为四甲基氟化铵,四甲基氟化铵用量为0.5克。Embodiment 17: a preparation method of D-gluconic acid-γ-lactone, the difference from embodiment 16 is: the dehydroxylation protection reagent is tetramethylammonium fluoride, and the amount of tetramethylammonium fluoride is 0.5 grams.
实施例18:一种D-葡萄糖酸-γ-内酯的制备方法,与实施例16的不同之处在于:所述脱羟基保护试剂为四乙基氟化铵,四乙基氟化铵用量为0.5克。Embodiment 18: a preparation method of D-gluconic acid-γ-lactone, the difference from embodiment 16 is: the dehydroxylation protection reagent is tetraethylammonium fluoride, and the amount of tetraethylammonium fluoride is 0.5 grams.
实施例19:一种D-葡萄糖酸-γ-内酯的制备方法,与实施例16的不同之处在于:所述脱羟基保护试剂为四乙基氟化铵,四乙基氟化铵用量为0.5克。Embodiment 19: a preparation method of D-gluconic acid-γ-lactone, the difference from embodiment 16 is: the dehydroxylation protection reagent is tetraethylammonium fluoride, and the amount of tetraethylammonium fluoride is 0.5 grams.
实施例20:一种D-葡萄糖酸-γ-内酯的制备方法,与实施例16的不同之处在于:所述脱羟基保护试剂为氟化钠,氟化钠的用量为0.5克。Embodiment 20: a preparation method of D-glucono-γ-lactone, which is different from Embodiment 16 in that the dehydroxylation protection reagent is sodium fluoride, and the amount of sodium fluoride is 0.5 g.
实施例21:一种D-葡萄糖酸-γ-内酯的制备方法,与实施例16的不同之处在于:所述脱羟基保护试剂为乙酸,乙酸的用量为0.5克。Example 21: A preparation method of D-glucono-γ-lactone, the difference from Example 16 is that the dehydroxylation protection reagent is acetic acid, and the amount of acetic acid is 0.5 g.
实施例22:一种D-葡萄糖酸-γ-内酯的制备方法,与实施例16的不同之处在于:所述脱羟基保护试剂为乙酸,乙酸的用量为5克。Example 22: A preparation method of D-glucono-γ-lactone, the difference from Example 16 is that the dehydroxylation protection reagent is acetic acid, and the amount of acetic acid is 5 grams.
实施例23:一种D-葡萄糖酸-γ-内酯的制备方法,与实施例16的不同之处在于:采用的D-葡萄糖酸-γ-内酯中间体选用实施例14中制得的D-葡萄糖酸-γ-内酯中间体。Embodiment 23: a preparation method of D-gluconic acid-γ-lactone, the difference from Example 16 is: the D-gluconic acid-γ-lactone intermediate used is selected from Example 14. D-glucono-γ-lactone intermediate.
实施例24:一种D-葡萄糖酸-γ-内酯的制备方法,与实施例16的不同之处在于:采用的D-葡萄糖酸-γ-内酯中间体选用实施例2中制得的D-葡萄糖酸-γ-内酯中间体。Embodiment 24: a kind of preparation method of D-gluconic acid-γ-lactone, the difference from Example 16 is: the D-gluconic acid-γ-lactone intermediate used is the one prepared in Example 2. D-glucono-γ-lactone intermediate.
实施例25:一种D-葡萄糖酸-γ-内酯的制备方法,与实施例16的不同之处在于:采用的D-葡萄糖酸-γ-内酯中间体选用实施例3中制得的D-葡萄糖酸-γ-内酯中间体。Embodiment 25: a kind of preparation method of D-gluconic acid-γ-lactone, the difference from Example 16 is: the D-gluconic acid-γ-lactone intermediate used is selected from the one prepared in Example 3. D-glucono-γ-lactone intermediate.
实施例26:一种D-葡萄糖酸-γ-内酯的制备方法,包括如下操作步骤:在氮气保护下,将TMS-葡萄糖内酯(50.0g,0.136mmol)加入到500ml的甲醇,室温(20℃)搅拌溶解后,加入5克的乙酸,室温(20℃)搅拌12小时,然后减压浓缩,加入200ml的乙醇加热溶解后,冷却至室温,加入少量晶种,析出大量固体,经布氏漏斗过滤得到固体。Embodiment 26: a kind of preparation method of D-glucono-γ-lactone, comprising the following operation steps: under nitrogen protection, TMS-glucolactone (50.0g, 0.136mmol) is added to 500ml of methanol, room temperature ( 20°C) after stirring and dissolving, add 5 grams of acetic acid, stir at room temperature (20°C) for 12 hours, then concentrate under reduced pressure, add 200ml of ethanol for heating and dissolving, cool to room temperature, add a small amount of seed crystals, and precipitate a large amount of solids. The solid was obtained by filtration through a Schenker funnel.
其中,上述合成D-葡萄糖酸-γ-内酯的化学方程式为:Wherein, the chemical equation of above-mentioned synthetic D-gluconic acid-γ-lactone is:
实施例27:一种D-葡萄糖酸-γ-内酯的制备方法,与实施例26的不同之处在于:室温(20℃)搅拌15小时。Embodiment 27: a preparation method of D-glucono-γ-lactone, which is different from Embodiment 26 in that the mixture is stirred at room temperature (20° C.) for 15 hours.
实施例28:一种D-葡萄糖酸-γ-内酯的制备方法,与实施例26的不同之处在于:室温(20℃)搅拌18小时。Example 28: A preparation method of D-glucono-γ-lactone, the difference from Example 26 is: stirring at room temperature (20° C.) for 18 hours.
实施例29:一种D-葡萄糖酸-γ-内酯的制备方法,与实施例26的不同之处在于:室温(25℃)搅拌12小时。Embodiment 29: a preparation method of D-glucono-γ-lactone, which is different from Embodiment 26 in that the mixture is stirred at room temperature (25° C.) for 12 hours.
实施例30:一种D-葡萄糖酸-γ-内酯的制备方法,与实施例26的不同之处在于:室温(15℃)搅拌12小时。Example 30: A preparation method of D-glucono-γ-lactone, the difference from Example 26 is: stirring at room temperature (15° C.) for 12 hours.
二、对比例2. Comparative ratio
<1>、D-葡萄糖酸-γ-内酯中间体<1>, D-glucono-γ-lactone intermediate
对比例1:一种D-葡萄糖酸-γ-内酯中间体的制备方法,与实施例1的不同之处在于:反应体系冷却至-30℃。Comparative Example 1: A preparation method of a D-glucono-γ-lactone intermediate, the difference from Example 1 is that the reaction system is cooled to -30°C.
对比例2:一种D-葡萄糖酸-γ-内酯中间体的制备方法,与实施例1的不同之处在于:反应体系冷却至100℃。Comparative Example 2: A preparation method of a D-glucono-γ-lactone intermediate, the difference from Example 1 is that the reaction system is cooled to 100°C.
对比例3:一种D-葡萄糖酸-γ-内酯中间体的制备方法,与实施例1的不同之处在于:硅烷基试剂RX为三乙基氯硅烷,用量为3当量。Comparative Example 3: A preparation method of a D-gluconic acid-γ-lactone intermediate, which is different from Example 1 in that the silyl reagent RX is triethylchlorosilane, and the amount is 3 equivalents.
<2>、D-葡萄糖酸-γ-内酯<2>, D-glucono-γ-lactone
对比例4:一种D-葡萄糖酸-γ-内酯的制备方法,与实施例1的不同之处在于:以D-(+)-葡萄糖,为起始物料,在氯化钙和碳酸钙和水条件下制备D-葡萄糖酸,然后溶解在二氧六环和水溶剂中制备D-葡萄糖酸-1,5-内酯,D-葡萄糖酸-1,5-内酯在乙酸和盐酸条件下转化为D-葡萄糖酸-γ-内酯。Comparative example 4: a preparation method of D-glucono-γ-lactone, the difference from Example 1 is: with D-(+)-glucose as starting material, in calcium chloride and calcium carbonate D-gluconic acid was prepared under the condition of and water, then dissolved in dioxane and water solvent to prepare D-glucono-1,5-lactone, D-glucono-1,5-lactone was prepared in the condition of acetic acid and hydrochloric acid down-converted to D-glucono-γ-lactone.
对比例5:一种D-葡萄糖酸-γ-内酯的制备方法,与实施例1的不同之处在于:以D-葡萄糖酸为起始物料,在水溶剂中通过高温转化为D-葡萄糖酸-γ-内酯和D-葡萄糖酸-1,5-内酯混合物。Comparative example 5: a kind of preparation method of D-gluconic acid-γ-lactone, the difference with embodiment 1 is: take D-gluconic acid as starting material, in water solvent, be converted into D-glucose by high temperature A mixture of acid-gamma-lactone and D-glucono-1,5-lactone.
三、性能检测分析试验一:D-葡萄糖酸-γ-内酯中间体的性能检测3. Performance testing and analysis Test 1: Performance testing of D-glucono-γ-lactone intermediates
试验对象:将实施例1-15制得的D-葡萄糖酸-γ-内酯中间体作为试验样品1-15,将对比例1-3制得的D-葡萄糖酸-γ-内酯中间体作为对照样品1-3。Test object: The D-glucono-γ-lactone intermediate prepared in Example 1-15 was used as test sample 1-15, and the D-glucono-γ-lactone intermediate prepared in Comparative Example 1-3 As control samples 1-3.
试验结果:如表1可知,试验样品1-15的产率均高于对照样品1-3。同时与试验样品1相比较,对照样品1和对照样品2的纯度与试验样品1相接近,但是对照样品1和对照样品2的产率远低于试验样品1的。其次,在试验样品4和试验样品5的产率也明显低于试验样品1-3;同时,试验样品2的产率最高。由此可知,当温度在-5~25℃时反应的产率较高,同时在反应温度为0℃时最佳。Test results: As can be seen in Table 1, the yields of test samples 1-15 are higher than those of control samples 1-3. At the same time, compared with test sample 1, the purity of control sample 1 and control sample 2 is close to that of test sample 1, but the yield of control sample 1 and control sample 2 is much lower than that of test sample 1. Secondly, the yields of test samples 4 and 5 are also significantly lower than those of test samples 1-3; at the same time, the yield of test sample 2 is the highest. It can be seen that the yield of the reaction is higher when the temperature is between -5 and 25°C, and the optimum reaction temperature is at 0°C.
另外,与对照样品3相比较,试验样品1-15的纯度均高于对照样品3的纯度。同时试验样品11、试样样品14以及试验样品15对比可知,试验样品11的纯度高于试样样品14以及试验样品15的。由此可知,碱性试剂的投料量与葡萄糖内酯的比例在4倍以上较佳,同时碱性试剂的投料量与葡萄糖内酯的比例为4.5倍时最佳。In addition, compared with the control sample 3, the purity of the test samples 1-15 is higher than that of the control sample 3. At the same time, by comparing the test sample 11, the sample sample 14 and the test sample 15, it can be seen that the purity of the test sample 11 is higher than that of the sample sample 14 and the test sample 15. It can be seen that the ratio of the feeding amount of the alkaline reagent to the glucolactone is preferably more than 4 times, and the best when the ratio of the feeding amount of the alkaline reagent to the glucolactone is 4.5 times.
表1试验样品1-15和对照样品1-3的产率和纯度测试结果Table 1 Test results of yield and purity of test samples 1-15 and control samples 1-3
试验二:D-葡萄糖酸-γ-内酯的性能检测Test 2: Performance testing of D-glucono-γ-lactone
试验对象:将实施例16-30制得的D-葡萄糖酸-γ-内酯作为试验样品16-30,将对比例4-5制得的D-葡萄糖酸-γ-内酯作为对照样品4-5。Test object: D-glucono-γ-lactone prepared in Example 16-30 was taken as test sample 16-30, and D-glucono-γ-lactone prepared in Comparative Example 4-5 was taken as control sample 4 -5.
试验结果:如表2可知,试样样品16-30的产率、纯度均高于对照样品4-5的。同时,对照样品4的产率接近试样样品16的产率的二分之一,同时对比试样样品21、22以及试样样品26可知,采用乙酸作为脱羟基保护试剂代替氟化物时,不能是仅仅是经乙酸换成氟化物即可,而需要调整乙酸的用量等。Test results: As shown in Table 2, the yield and purity of sample samples 16-30 are higher than those of control samples 4-5. At the same time, the yield of the control sample 4 is close to half of the yield of the sample sample 16, while comparing the sample samples 21, 22 and 26, it can be seen that when acetic acid is used as the dehydroxylation protection reagent instead of the fluoride, the It is only necessary to replace the acetic acid with fluoride, and the amount of acetic acid needs to be adjusted.
表2试验样品16-30和对照样品4-5的产率和纯度测试结果Table 2 The yield and purity test results of test samples 16-30 and control samples 4-5
具体实施例仅仅是对本发明的解释,其并不是对本发明的限制,本领域技术人员在阅读完本说明书后可以根据需要对本实施例做出没有创造性贡献的修改,但只要在本发明的权利要求范围内都受到专利法的保护。The specific embodiment is only an explanation of the present invention, and it is not a limitation of the present invention. Those skilled in the art can make modifications to the present embodiment without creative contribution as needed after reading this specification, but only in the claims of the present invention are protected by patent law.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911205131.2A CN110759941B (en) | 2019-11-29 | 2019-11-29 | Preparation method of D-gluconic acid-gamma-lactone and intermediate thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911205131.2A CN110759941B (en) | 2019-11-29 | 2019-11-29 | Preparation method of D-gluconic acid-gamma-lactone and intermediate thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110759941A CN110759941A (en) | 2020-02-07 |
CN110759941B true CN110759941B (en) | 2022-08-30 |
Family
ID=69340243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911205131.2A Expired - Fee Related CN110759941B (en) | 2019-11-29 | 2019-11-29 | Preparation method of D-gluconic acid-gamma-lactone and intermediate thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110759941B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110903315A (en) * | 2019-12-16 | 2020-03-24 | 上海网义化工有限公司 | Preparation method of D-gluconic acid-gamma-lactone intermediate |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1993366A (en) * | 2004-06-30 | 2007-07-04 | 纳幕尔杜邦公司 | Synthesis of aldonolactones, aldarolactones, and aldarodilactones using gas sparging |
CN102574829A (en) * | 2009-09-30 | 2012-07-11 | 贝林格尔.英格海姆国际有限公司 | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
CN105481915A (en) * | 2014-09-19 | 2016-04-13 | 北京万生药业有限责任公司 | Preparation method of SGLT-2 inhibitor compound |
WO2016142950A1 (en) * | 2015-03-11 | 2016-09-15 | Harman Finochem Limited | A novel process for preparing (2s,3r,4r,5s,6r)-2-{3-[5-[4-fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol and its stable amorphous hemihydrate form |
-
2019
- 2019-11-29 CN CN201911205131.2A patent/CN110759941B/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1993366A (en) * | 2004-06-30 | 2007-07-04 | 纳幕尔杜邦公司 | Synthesis of aldonolactones, aldarolactones, and aldarodilactones using gas sparging |
CN102574829A (en) * | 2009-09-30 | 2012-07-11 | 贝林格尔.英格海姆国际有限公司 | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives |
CN105481915A (en) * | 2014-09-19 | 2016-04-13 | 北京万生药业有限责任公司 | Preparation method of SGLT-2 inhibitor compound |
WO2016142950A1 (en) * | 2015-03-11 | 2016-09-15 | Harman Finochem Limited | A novel process for preparing (2s,3r,4r,5s,6r)-2-{3-[5-[4-fluoro-phenyl)- thiophen-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5- triol and its stable amorphous hemihydrate form |
Non-Patent Citations (2)
Title |
---|
MAOS of D-Gluconic Acid,D-Glucono-1,4- and 1,5-Lactones, Estets, Hydrazides, and Benzimidazoles Thereof;E.S.H.EI Ashry et al.,;《Journal of Carbohydrate Chemistry》;20070622;第26卷;第329-338页,参见第334页第1段 * |
达格列净的合成;罗海荣等,;《精细石油化工》;20190731;第36卷(第4期);第53-57页,参见第53页左栏第1段 * |
Also Published As
Publication number | Publication date |
---|---|
CN110759941A (en) | 2020-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7267508B2 (en) | Manufacturing method of losartan | |
JP2019510128A (en) | Improved process for the preparation of Sugamadex | |
WO2009073462A1 (en) | Process for the preparation of 5-cyclopropyl-5, 11-dihydro (1) benzoxepino (3, 4-b) -pyridin-5-ol using tmeda | |
CN102617607B (en) | Method for preparing cefazolin compounds | |
CN102010426A (en) | Method for preparing ceftizoxime sodium | |
CN110759941B (en) | Preparation method of D-gluconic acid-gamma-lactone and intermediate thereof | |
CN119013269A (en) | Crystal form of alkynyl pyridine compound and preparation method thereof | |
CN112812107B (en) | Preparation method of SGLT-2 inhibitor and intermediate | |
CN104193765B (en) | A kind of synthetic method of cefixime | |
US9409940B2 (en) | Preparation process of erythromycin thiocyanate | |
CN104072516A (en) | Method for synthesizing cefuroxime acid | |
CN111072660A (en) | Simple preparation method of rilibatan | |
CN105712919A (en) | Application of amide condensing agent in vildagliptin synthetic method | |
CN116239493B (en) | Synthesis method of Linker compound | |
CN106632312B (en) | A kind of related substance of Eliquis, intermediate, preparation method and applications | |
CN104761599B (en) | A kind of preparation method of the O D glucuronic acids of 5,4 ' dihydroxyflavone 7 | |
CN109456275A (en) | A kind of preparation method of 1H-1,2,3- triazole | |
CN100357294C (en) | Novel crystal of 7- 2-(2-aminothiazole-4-yl)-2-hydroxyiminoa cetamido-3-vinyl-3-cephem-4-carboxylic acid (syn isomer) and method for preparation thereof | |
JP4892821B2 (en) | Epalrestat manufacturing method | |
US20110282064A1 (en) | Method for the manufacture of highly pure prasugrel | |
CN115093431A (en) | A kind of method of synthesizing cefpodoxime axetil | |
EP1619181B1 (en) | Processes for the preparation of gabapentin | |
CN113045491B (en) | Preparation method of lenvatinib and intermediate | |
CN107365359B (en) | Synthesis method of vancomycin chiral functional monomer | |
CN114560897B (en) | Post-treatment method for preparing fully-benzoylated glucose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220830 |
|
CF01 | Termination of patent right due to non-payment of annual fee |